TheraRadar
← Back
Data updated: Jun 28, 2026

AIR LIQUIDE LARGE INDUSTRIES US LP

Pharma
Pharmaceuticals

AIR LIQUIDE LARGE INDUSTRIES US LP is a pharmaceutical company with 2 FDA-approved products.

2013
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

AIR LIQUIDE LARGE INDUSTRIES US LP's Key Drugs

AIR LIQUIDE LARGE INDUSTRIES US LP's core commercial portfolio centers on NITROGEN, NF, OXYGEN, USP — its most strategically important drugs approved in the last 15 years.

NITROGEN, NF
Other
Approved 2013
OXYGEN, USP
Respiratory
Approved 2013

AIR LIQUIDE LARGE INDUSTRIES US LP's Recent FDA Approvals

New NDA/BLA approvals for AIR LIQUIDE LARGE INDUSTRIES US LP over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AIR LIQUIDE LARGE INDUSTRIES US LP's Therapeutic Areas

Disease areas where AIR LIQUIDE LARGE INDUSTRIES US LP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AIR LIQUIDE LARGE INDUSTRIES US LP Pipeline Snapshot

Active clinical trials for AIR LIQUIDE LARGE INDUSTRIES US LP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • NITROGEN, NF leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling